Stay updated on Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial
Sign up to get notified when there's something new on the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page.

Latest updates to the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedRevision metadata updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check60 days agoChange DetectedA site-wide update to revision v3.4.2 was applied and a government funding notice was removed; there are no changes to the study details, eligibility criteria, or results on this page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check67 days agoChange DetectedA site-wide notice about government funding status was added, and the page version was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check74 days agoChange DetectedAdded a 'Show glossary' option and updated metadata labels to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', while removing the previous lowercase variants. The page revision header now shows Revision: v3.4.0 instead of v3.3.4.SummaryDifference0.2%

- Check88 days agoChange DetectedThe page now displays Revision: v3.3.4 in place of the previous v3.3.3.SummaryDifference0.1%

Stay in the know with updates to Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page.